These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29131875)

  • 1. Association of LRRK2 Haplotype With Age at Onset in Parkinson Disease.
    Xiao B; Deng X; Ng EY; Allen JC; Lim SY; Ahmad-Annuar A; Tan EK
    JAMA Neurol; 2018 Jan; 75(1):127-128. PubMed ID: 29131875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2 and the new era of Parkinson's disease research.
    The Lancet Neurology
    Lancet Neurol; 2016 Nov; 15(12):1195. PubMed ID: 27751534
    [No Abstract]   [Full Text] [Related]  

  • 3. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
    Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
    Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.
    Fernández-Santiago R; Garrido A; Infante J; González-Aramburu I; Sierra M; Fernández M; Valldeoriola F; Muñoz E; Compta Y; Martí MJ; Ríos J; Tolosa E; Ezquerra M;
    Mov Disord; 2018 Apr; 33(4):637-641. PubMed ID: 29473656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2 gene in Parkinson disease: mutation analysis and case control association study.
    Paisán-Ruíz C; Lang AE; Kawarai T; Sato C; Salehi-Rad S; Fisman GK; Al-Khairallah T; St George-Hyslop P; Singleton A; Rogaeva E
    Neurology; 2005 Sep; 65(5):696-700. PubMed ID: 16157901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease.
    Correia Guedes L; Reimão S; Paulino P; Nunes RG; Bouça-Machado R; Abreu D; Gonçalves N; Soares T; Fabbri M; Godinho C; Pita Lobo P; Neutel D; Quadri M; Coelho M; Rosa MM; Campos J; Outeiro TF; Sampaio C; Bonifati V; Ferreira JJ
    Mov Disord; 2017 Sep; 32(9):1331-1333. PubMed ID: 28686310
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathophysiological heterogeneity in Parkinson's disease: Neurophysiological insights from LRRK2 mutations.
    Kojovic M; Kassavetis P; Pareés I; Georgiev D; Rocchi L; Balint B; Foltynie T; Rothwell J; Bhatia K
    Mov Disord; 2017 Sep; 32(9):1333-1335. PubMed ID: 28686318
    [No Abstract]   [Full Text] [Related]  

  • 8. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
    Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
    Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease.
    Rouaud T; Clairembault T; Coron E; Neunlist M; Anheim M; Derkinderen P
    Parkinsonism Relat Disord; 2017 Jul; 40():83-84. PubMed ID: 28483388
    [No Abstract]   [Full Text] [Related]  

  • 11. Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.
    Visanji NP; Bhudhikanok GS; Mestre TA; Ghate T; Udupa K; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kim S; Azhu Valappil R; Kausar F; Rogaeva E; William Langston J; Tanner CM; Schüle B; Lang AE; Goldman SM; Marras C
    Mov Disord; 2017 Apr; 32(4):610-614. PubMed ID: 28071824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased substantia nigra echogenicity in LRRK2 family members without mutations.
    Pullman M; Ortega R; Glickman A; Deik A; Raymond D; Marder K; Giladi N; Bressman S; Hagenah J; Brüggemann N; Saunders-Pullman R
    Mov Disord; 2018 Sep; 33(9):1504-1505. PubMed ID: 30145825
    [No Abstract]   [Full Text] [Related]  

  • 13. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
    Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LARGE-PD: Examining the genetics of Parkinson's disease in Latin America.
    Zabetian CP; Mata IF;
    Mov Disord; 2017 Sep; 32(9):1330-1331. PubMed ID: 28657124
    [No Abstract]   [Full Text] [Related]  

  • 15. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of LRRK2 and GBA mutations in a Brazilian family with Parkinson's disease.
    Spitz M; Pereira JS; Nicareta DH; Abreu Gde M; Bastos EF; Seixas TL; Pimentel MM
    Parkinsonism Relat Disord; 2015 Jul; 21(7):825-6. PubMed ID: 25952961
    [No Abstract]   [Full Text] [Related]  

  • 17. A novel rare variant of LRRK2 associated with familial Parkinson's disease: p.R1501W.
    Masuzugawa S; Nishioka K; Imai Y; Ogata J; Shojima Y; Li Y; Yoshino H; Hattori N
    Parkinsonism Relat Disord; 2020 Jul; 76():46-48. PubMed ID: 32563051
    [No Abstract]   [Full Text] [Related]  

  • 18. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
    Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
    Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2 pathobiology in Parkinson's disease - virtual inclusion.
    Martin I; Kim JW; Dawson VL; Dawson TM
    J Neurochem; 2016 Oct; 139 Suppl 1():75-76. PubMed ID: 26899799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease.
    da Silva CP; de M Abreu G; Cabello Acero PH; Campos M; Pereira JS; de A Ramos SR; Nascimento CM; Voigt DD; Rosso AL; Araujo Leite MA; Vasconcellos LFR; Nicaretta DH; Della Coletta MV; da Silva DJ; Gonçalves AP; Dos Santos JM; Calassara V; Valença DCT; de M Martins CJ; Santos-Rebouças CB; Pimentel MMG
    J Neurol Sci; 2017 Oct; 381():160-164. PubMed ID: 28991672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.